{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:55:36Z","timestamp":1795042536473,"version":"4.10.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the age-related efficacy and safety of atropine 0.01% eye drops over 2\u00a0years for myopia control in a multicentric pediatric Spanish cohort. A non-controlled, interventional, prospective multicenter study was conducted as an extension of the Spanish Group of Atropine Treatment for Myopia Control Study (GTAM 1). Children aged 6\u201314\u00a0years with myopia from \u2212\u00a02.00 to \u2212\u00a06.00\u00a0D, astigmatism\u2009&lt;\u20091.50\u00a0D and documented annual myopic progression of at least \u2212\u00a00.50\u00a0D under cycloplegic examination were recruited. From the original cohort of 105 participants, 92 children who had been receiving atropine 0.01% eye drops once nightly in each eye for 1\u00a0year continued their participation in this extended study (GTAM 2). All the patients underwent a standardized quarterly follow-up protocol, which included measurements of best-corrected visual acuity (BCVA), cycloplegic autorefraction, axial length (AL), anterior chamber depth (ACD), and pupil diameter. The study sample was divided into three age groups: 6\u20138, 9\u201311, and 12\u201314\u00a0years old. The mean change in cycloplegic spherical equivalent (SE) and axial length (AL) during the 24\u00a0months of follow-up was analyzed. Correlations between SE and AL, as well as the distribution of annual progression, were evaluated. Adverse effects were recorded using a specific questionnaire. Finally, 81 children completed the follow-up and were included in the analysis. Over the 2-year period, the mean changes in SE and AL were \u2212\u00a00.88\u2009\u00b1\u20090.60\u00a0D and 0.49\u2009\u00b1\u20090.25\u00a0mm, respectively. Additionally, 51 patients (63%) experienced SE annual progression lower than \u2212\u00a00.50\u00a0D. The correlation between the progression of SE and AL during the total period of treatment was mild (r\u2009=\u2009\u2212\u00a00.36; p\u2009&lt;\u20090.001). There were no differences between the first and the second year of treatment in the progression of SE (\u2212\u00a00.42\u2009\u00b1\u20090.41\u00a0D versus \u2212\u00a00.45\u2009\u00b1\u20090.39\u00a0D; p\u2009=\u20090.69) or AL (0.25\u2009\u00b1\u20090.16\u00a0mm versus 0.23\u2009\u00b1\u20090.14\u00a0mm; p\u2009=\u20090.43). Older patients (12\u201314\u00a0years old) showed less AL progression than younger children (6\u20138\u00a0years old): 0.36\u2009\u00b1\u20090.18\u00a0mm versus 0.59\u2009\u00b1\u20090.30\u00a0mm; p\u2009=\u20090.01. Adverse effects were mild, infrequent, and decreased over time. On average, the myopia progression in control groups from other published biannual studies exceeded that observed in our study. Over 2\u00a0years, atropine 0.01% demonstrated a safe treatment for controlling myopia progression in a multicentric cohort of Spanish children. The effect remained stable during this period. Older patients exhibited a more favorable response in terms of AL enlargement. However, further studies are needed to investigate the age-related effect of low-dose atropine in the Caucasian population.<\/jats:p>","DOI":"10.1038\/s41598-023-43569-x","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T11:02:16Z","timestamp":1695898936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Age-related results over 2\u00a0years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression"],"prefix":"10.1038","volume":"13","author":[{"given":"In\u00e9s","family":"P\u00e9rez-Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mac\u00edas-Murelaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Multicenter Group of Atropine Treatment for Myopia Control (GTAM)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s P\u00e9rez","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Valc\u00e1rcel","family":"Vizca\u00edno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Garc\u00eda","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Catal\u00e1n","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Rodr\u00edguez","family":"Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Iglesias","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Lorente","family":"Bulnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas Garc\u00eda-Anllo","family":"Reinoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Carnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"de Rojas Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Barrio Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Rodr\u00edguez","family":"Feijoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Rodr\u00edguez","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argentina Rosario Calvo","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia L\u00f3pez-Romero","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela Barraj\u00f3n","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier G\u00e1lvez","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Victoria Mesa","family":"Carina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Gal\u00e1n","family":"Risue\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Rodr\u00edguez","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Barrio-Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"43569_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden, B. A. et al. Global prevalence of myopya and high myopia and temporal trends from 2000 to 2050. Ophthalmology 123, 1036\u20131042 (2016).","journal-title":"Ophthalmology"},{"key":"43569_CR2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ophtha.2015.03.018","volume":"122","author":"K Williams","year":"2015","unstructured":"Williams, K. et al. Increasing prevalence of myopia in Europe and the impect of education. Ophthalmology 122, 1489\u20131497 (2015).","journal-title":"Ophthalmology"},{"key":"43569_CR3","doi-asserted-by":"publisher","first-page":"8173","DOI":"10.1038\/s41598-020-65130-w","volume":"10","author":"D Pusti","year":"2020","unstructured":"Pusti, D., Benito, A., Madrid-Valero, J., Ordo\u00f1ana, J. & Artal, P. Inheritance of refractive error in millenials. Sci. Rep. 10, 8173. https:\/\/doi.org\/10.1038\/s41598-020-65130-w (2020).","journal-title":"Sci. Rep."},{"key":"43569_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12886-019-1220-0","volume":"20","author":"A Grzybowski","year":"2020","unstructured":"Grzybowski, A., Kanclerz, P., Tsubota, K., Lanca, C. & Saw, S. M. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol. 20, 27. https:\/\/doi.org\/10.1186\/s12886-019-1220-0 (2020).","journal-title":"BMC Ophthalmol."},{"key":"43569_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/1120672121998960","volume":"31","author":"J N\u00e9meth","year":"2021","unstructured":"N\u00e9meth, J. et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur. J. Ophthalmol. 31, 853\u2013883 (2021).","journal-title":"Eur. J. Ophthalmol."},{"key":"43569_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.64.6.6","volume":"64","author":"JS Wolffsohn","year":"2022","unstructured":"Wolffsohn, J. S., Whayeb, Y., Logan, N. S. & Weng, N. IMI-Global Trends in myopia management attitudes an strategies in clinical practice-2022 update. Invest. Ophthalmol. Vis. Sci. 64, 6. https:\/\/doi.org\/10.1167\/iovs.64.6.6 (2022).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"43569_CR7","doi-asserted-by":"publisher","first-page":"CD014758","DOI":"10.1002\/14651858.CD014758.pub.2","volume":"2","author":"JG Lawrenson","year":"2023","unstructured":"Lawrenson, J. G. et al. Interventions for myopia control in children: A living systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2, CD014758. https:\/\/doi.org\/10.1002\/14651858.CD014758.pub.2 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"43569_CR8","doi-asserted-by":"publisher","first-page":"CD004916","DOI":"10.1002\/1451858.CD004916.pub.4","volume":"1","author":"JJ Walline","year":"2011","unstructured":"Walline, J. J. et al. Interventions to slow progression of myopia in children. Cochrane Database Syst. Rev. 1, CD004916. https:\/\/doi.org\/10.1002\/1451858.CD004916.pub.4 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"43569_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","volume":"124","author":"SL Pineles","year":"2017","unstructured":"Pineles, S. L. et al. Atropine for the prevention of myopia progression in children: A report by the American Academy of Ophthalmology. Ophthalmology 124, 1857\u20131866 (2017).","journal-title":"Ophthalmology"},{"key":"43569_CR10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua, W. H. et al. Atropine for the treatment of chilhood myopia. Ophthalmology 113, 2285\u20132291 (2006).","journal-title":"Ophthalmology"},{"key":"43569_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia, A. et al. Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1% and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology 119, 347\u2013354 (2012).","journal-title":"Ophthalmology"},{"key":"43569_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam, J. C. et al. Two-year clinical trial of the Low-Concentration Atropine for Myopia Progression (LAMP) study: Phase 2 report. Ophthalmology 127, 910\u2013919 (2020).","journal-title":"Ophthalmology"},{"key":"43569_CR13","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","volume":"41","author":"L Joachimsen","year":"2021","unstructured":"Joachimsen, L. et al. Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: A pilot study. Int. Ophthalmol. 41, 2001\u20132008 (2021).","journal-title":"Int. Ophthalmol."},{"key":"43569_CR14","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3390\/jcm12062314","volume":"12","author":"D Simonaviciute","year":"2023","unstructured":"Simonaviciute, D. et al. The effectiveness and tolerability of atropine eye drops for myopia control in non-asian regions. J. Clin. Med. 12, 2314. https:\/\/doi.org\/10.3390\/jcm12062314 (2023).","journal-title":"J. Clin. Med."},{"key":"43569_CR15","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00417-018-4078-6","volume":"256","author":"O Zloto","year":"2018","unstructured":"Zloto, O. et al. Current trends among pediatric ophthalmologists to decrease myopia progression-an international perspective. Graefes Arch. Clin. Exp. Ophthalmol. 256, 2457\u20132466 (2018).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"43569_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1055\/a-2013-2713","volume":"240","author":"LS Eppenberger","year":"2023","unstructured":"Eppenberger, L. S. & Sturm, V. Myopia management in daily-routine\u2014a survey of european pediatric ophthalmologists. Klin. Monbl. Augenheilkd. 240, 581\u2013586 (2023).","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"43569_CR17","doi-asserted-by":"publisher","first-page":"21748","DOI":"10.1038\/s41598-021-00923-1","volume":"11","author":"I P\u00e9rez-Flores","year":"2021","unstructured":"P\u00e9rez-Flores, I. et al. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci. Rep. 11, 21748. https:\/\/doi.org\/10.1038\/s41598-021-00923-1 (2021).","journal-title":"Sci. Rep."},{"key":"43569_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia, A., Lu, Q. S. & Tan, D. Five-year clinical trial on atropine for treatment of myopia 2: Myopia Control with Atropine. Ophthalmology 123, 391\u2013399 (2016).","journal-title":"Ophthalmology"},{"key":"43569_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","volume":"159","author":"K-L Loh","year":"2015","unstructured":"Loh, K.-L., Lu, Q., Tan, D. & Chia, A. Risks factors for progressive myopia in the atropine therapy for myopia study. Am. J. Ophthalmol. 159, 945\u2013949 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"43569_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","volume":"128","author":"FF Li","year":"2021","unstructured":"Li, F. F. et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine. Low-concentration atropine for myopia progression study. Ophthalmology 128, 1180\u20131187 (2021).","journal-title":"Ophthalmology"},{"key":"43569_CR21","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","volume":"11","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: A 2-year clinical trial. Sci. Rep. 11, 22267. https:\/\/doi.org\/10.1038\/s41598-021-01708-2 (2021).","journal-title":"Sci. Rep."},{"key":"43569_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ophtha.2023.02.020","volume":"130","author":"MA Bullimore","year":"2023","unstructured":"Bullimore, M. A. & Brennan, N. A. Efficacy in myopia control: The low-concentration atropine for myopia progression (LAMP) study. Ophthalmology 130, 771\u2013772 (2023).","journal-title":"Ophthalmology"},{"key":"43569_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda, O. et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn. J. Ophthalmol. 65, 315\u2013325 (2021).","journal-title":"Jpn. J. Ophthalmol."},{"key":"43569_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40123-019-00217-w","volume":"8","author":"GL Larkin","year":"2019","unstructured":"Larkin, G. L. et al. Atropine 0.01% eye drops for myopia control in american children: A multiethnic sample across three US sites. Ophthalmol. Ther. 8, 589\u2013598 (2019).","journal-title":"Ophthalmol. Ther."},{"key":"43569_CR25","doi-asserted-by":"publisher","first-page":"e232097","DOI":"10.1001\/jamaophthaolmol.2023.2097","volume":"2023","author":"K Zadnik","year":"2023","unstructured":"Zadnik, K. et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: A randomized clinical trial. JAMA Ophthalmol. 2023, e232097. https:\/\/doi.org\/10.1001\/jamaophthaolmol.2023.2097 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"43569_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","volume":"44","author":"M Moriche-Carretero","year":"2021","unstructured":"Moriche-Carretero, M., Revilla-Amores, R., D\u00edaz-Valle, D., Morales-Fernandez, L. & G\u00f3mez-de-Lia\u00f1o, R. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops. J. Fr. Opthalmol. 44, 1499\u20131504 (2021).","journal-title":"J. Fr. Opthalmol."},{"key":"43569_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-322808","author":"M Moriche-Carretero","year":"2023","unstructured":"Moriche-Carretero, M. et al. Five-years results of atropine 0.01% efficacy in the myopia control in an European population. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjo-2022-322808 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"43569_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.optom.2019.06.002","volume":"13","author":"K Wong","year":"2020","unstructured":"Wong, K. & Dahlmann-Noor, A. Myopia and its progression in children in London, UK: A retrospective evaluation. J. Optom. 13, 146\u2013154 (2020).","journal-title":"J. Optom."},{"key":"43569_CR29","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1038\/s41598-02210978-3","volume":"12","author":"LC Lee","year":"2022","unstructured":"Lee, L. C., Hsieh, M. W., Chen, Y. H., Chen, P. L. & Chien, K. H. Characteristics of responders to atropine 0.01% as treatment in Asian myopic children. Sci. Rep. 12, 7380. https:\/\/doi.org\/10.1038\/s41598-02210978-3 (2022).","journal-title":"Sci. Rep."},{"key":"43569_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha, A., Kim, S. J., Shim, S. R., Kim, Y. K. & Jung, J. H. Efficacy and safety of 8 atropine concentrations for myopia control in children: A network meta-analysis. Ophthalmology 129, 322\u2013333 (2022).","journal-title":"Ophthalmology"},{"key":"43569_CR31","first-page":"e137","volume":"15","author":"MM Galan","year":"2022","unstructured":"Galan, M. M. et al. Consensus on progressive myopia management. Myopia Study Group of the Argentine Society of Paediatric Ophthalmology. Oftalmol. Clin. Exp. 15, e137\u2013e156 (2022).","journal-title":"Oftalmol. Clin. Exp."},{"key":"43569_CR32","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SS-Y Lee","year":"2022","unstructured":"Lee, S.S.-Y. et al. Low-concentration atropine eyedrops for myopia controlin a multi-racial cohort of Australian children: A randomised clinical trial. Clin. Exp. Ophthalmol. 50, 1001\u20131012 (2022).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"43569_CR33","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1007\/s00417-021-05254-5","volume":"259","author":"H Kaymak","year":"2021","unstructured":"Kaymak, H. et al. A retrospective analysis of the therapeutic effects of 0.01% atropine on axial lenght growth in children in a real-life clinical setting. Graefes Arch. Clin. Exp. Ophthalmol. 259, 3082\u20133092 (2021).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"43569_CR34","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.3390\/jcm10173766","volume":"10","author":"HR Tsai","year":"2021","unstructured":"Tsai, H. R., Chen, T. L., Wang, J. H., Huang, W. K. & Chiu, C. J. Is 0.01% Atropine an effective and safe treatment for myopic children? A systematic review and meta-analysis. J. Clin. Med. 10, 3766. https:\/\/doi.org\/10.3390\/jcm10173766 (2021).","journal-title":"J. Clin. Med."},{"key":"43569_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia, A. et al. Atropine for the treatment of chilhood myopia: Changes after stoppng atropine 0.01%, 0.1% and 0.5%. Am. J. Ophthalmol. 157, 451\u2013457 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"43569_CR36","doi-asserted-by":"publisher","first-page":"756398","DOI":"10.3389\/fmed.2021.756398","volume":"8","author":"J Gan","year":"2022","unstructured":"Gan, J. et al. Varying dose of atropine in slowing myopia progression in children over different follow-up preiods by meta-analysis. Front. Med. 8, 756398. https:\/\/doi.org\/10.3389\/fmed.2021.756398 (2022).","journal-title":"Front. Med."},{"key":"43569_CR37","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.ophtha.2021.04.001","volume":"128","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. COVID-19 Quarantine reveals that behavioral changes have an effect on myopia progression. Ophthalmology 128, 1652\u20131654 (2021).","journal-title":"Ophthalmology"},{"key":"43569_CR38","doi-asserted-by":"publisher","first-page":"101475","DOI":"10.1016\/j.clae.2021.101475","volume":"45","author":"N Erdinest","year":"2022","unstructured":"Erdinest, N. et al. Decreased effectiveness of 0.01% atropine treatment fot myopia control during prolonged COVID-19 lockdowns. Cont. Lens Anterior Eye 45, 101475. https:\/\/doi.org\/10.1016\/j.clae.2021.101475 (2022).","journal-title":"Cont. Lens Anterior Eye"},{"key":"43569_CR39","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei, S. et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in chinese children: Arandomized clinical trial. JAMA Ophthalmol. 138, 1178\u20131184 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"43569_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.62.10.36","volume":"62","author":"LA Jones-Jordan","year":"2021","unstructured":"Jones-Jordan, L. A. et al. Myopia progression as function of sex, age and ethnicity. Invest. Ophthalmol. Vis. Sci. 62, 36. https:\/\/doi.org\/10.1167\/iovs.62.10.36 (2021).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"43569_CR41","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1177\/11206721211038817","volume":"32","author":"GS Jeon","year":"2022","unstructured":"Jeon, G. S. et al. Analysis of treatment response about low-dose (0.01%) atropine eye-drops in myopic children. Eur. J. Ophthalmol. 32, 2011\u20132017 (2022).","journal-title":"Eur. J. Ophthalmol."},{"key":"43569_CR42","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1038\/s41598-022-10079-1(","volume":"12","author":"S Chaurasia","year":"2022","unstructured":"Chaurasia, S. et al. Efficacy of 0.01% low dose atropine and its correlatioin with various factors in myopia control in the Indian population. Sci. Rep. 12, 7113. https:\/\/doi.org\/10.1038\/s41598-022-10079-1( (2022).","journal-title":"Sci. Rep."},{"key":"43569_CR43","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam, J. C. et al. Three-year clinical trial of Low Concentration Atropine for Myopia Progression Study: Continued versus whasout. Phase 3 report. Ophthalmology 129, 308\u2013321 (2022).","journal-title":"Ophthalmology"},{"key":"43569_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/aos.13603","volume":"96","author":"J Tideman","year":"2018","unstructured":"Tideman, J. et al. Axial lengh growth and the risk of developing myopia in European children. Acta Ophthalmol. 96, 301\u2013309 (2018).","journal-title":"Acta Ophthalmol."},{"key":"43569_CR45","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1038\/s41958-020-72240-y","volume":"10","author":"S McCullough","year":"2020","unstructured":"McCullough, S. et al. Axial growth and refractive change in white European children and young adults: Predictive factors for myopia. Sci. Rep. 10, 15189. https:\/\/doi.org\/10.1038\/s41958-020-72240-y (2020).","journal-title":"Sci. Rep."},{"key":"43569_CR46","first-page":"257","volume":"63","author":"W Shamp","year":"2022","unstructured":"Shamp, W., Brennan, N., Bullimore, M., Cheng, X. & Maynes, E. Influence of age and race on axial elongation in myopic children. Invest. Ophthalmol. Vis. Sci. 63, 257 (2022).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"43569_CR47","doi-asserted-by":"publisher","unstructured":"Chan, H.H. Efficacy of 0.01% atropine for myopia control in a randomized, placebo-control trial depends on baseline electroretinal response. Sci Reports. 12, 11588 ; https:\/\/doi.org\/10.1038\/s41598-022-15686-6 (2022).","DOI":"10.1038\/s41598-022-15686-6"},{"key":"43569_CR48","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ophtha.2020.06.004","volume":"127","author":"FF Li","year":"2020","unstructured":"Li, F. F. et al. Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine. Low-concentration atropine for myopia progression study. Ophthalmology 127, 1603\u20131611 (2020).","journal-title":"Ophthalmology"},{"key":"43569_CR49","first-page":"1535","volume":"104","author":"A Fu","year":"2020","unstructured":"Fu, A. et al. Effect of low-dosw atropine on myopia progression, pupil diameter and accommodative amplitude: Low-dose atropine and myopia progression. Br. J. Ophthalmol. 104, 1535\u20131541 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"43569_CR50","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1136\/bjophthalmol-2015-307861","volume":"100","author":"J Loughman","year":"2016","unstructured":"Loughman, J. & Flitcroft, D. I. The acceptability and visual impact of 0.01% atropine in a Caucasian population. Br. J. Ophthalmol. 100, 1525\u20131529 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"43569_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","volume":"48","author":"K Richdale","year":"2022","unstructured":"Richdale, K., TomiYm, E. S., Nocack, G. D. & Bullimore, M. A. Compounding of low-concentration atropine for myopia control. Eye Contact Lens 48, 489\u2013492 (2022).","journal-title":"Eye Contact Lens"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43569-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:20:20Z","timestamp":1700277620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43569-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43569"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43569-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"29 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16310"}}